Bluejay Achieves Toray Contractual Manufacturing Milestone, Advancing Supply-Chain Resilience and Commercialization Readiness
Manufacturing plans span Japan and the United States, with complementary pathways intended to reduce reliance on a single manufacturing route.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Bluejay Diagnostics (BJDX) completed establishment of a Symphony cartridge manufacturing site, meeting a contractual milestone under its amended Toray Industries license agreement.
The milestone was achieved ahead of the October 23, 2026 deadline, and Bluejay formally notified Toray that its obligation to substantially complete site establishment had been fulfilled. SanyoSeiko in Japan serves as the contractual manufacturing site. Bluejay is developing complementary manufacturing capabilities there and with ALURIS Sciences in the United States, intended to reduce reliance on a single manufacturing pathway. Manufacturing scale-up continues alongside the regulatory program for the Symphony IL-6 Test. The test has not received FDA clearance or approval and is not available for commercial clinical use in the United States.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointSymphony cartridge manufacturing site establishment met the Toray contractual milestone ahead of the October 23, 2026 deadline.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Complementary capabilities at SanyoSeiko and ALURIS Sciences are being developed to reduce single-pathway manufacturing reliance.
- Minor pointManufacturing scale-up continues alongside the Symphony IL-6 Test regulatory program.
Negative
- None.
Details
Market move: BJDX -4.06% vs previous close. contractual manufacturing milestone
On Oct 13, the day this news came out, the latest delayed price for BJDX is 4.06% below the previous close. Argus tracked a peak move of +3.6% during the session. Our momentum scanner has recorded 7 alerts for this stock so far that day. The latest delayed price is $0.76. Relative volume is exceptionally heavy at 36.0x the average.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Contractual deadline
- October 23, 2026
- Manufacturing-site establishment under the amended Toray license agreement; milestone achieved ahead of deadline
Key Terms
il-6 medical
510(k) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
ACTON, MA / ACCESS Newswire / October 13, 2026 / Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical diagnostics company focused on improving patient outcomes through its Symphony™ near-patient diagnostic platform, today announced that it has completed the establishment of a manufacturing site for Symphony™ cartridges, achieving a critical contractual milestone as the Company advances toward regulatory submission and potential commercialization.
The milestone was achieved ahead of the October 23, 2026 contractual deadline established under Bluejay's amended license agreement with Toray Industries, Inc. ("Toray"). Bluejay has formally notified Toray that the Company has fulfilled its obligation to substantially complete establishment of a manufacturing site. Bluejay's manufacturing strategy is being developed around complementary manufacturing capabilities at SanyoSeiko Co., Ltd. in Japan and ALURIS Sciences, (previously Argonaut Manufacturing Services) in the United States. SanyoSeiko serves as the manufacturing site established under Bluejay's agreement with Toray and is an important component of the Company's Symphony cartridge manufacturing infrastructure.
Together, these initiatives are intended to provide Bluejay with a more diversified and resilient manufacturing infrastructure, reducing reliance on a single manufacturing pathway while increasing operational flexibility as the Company prepares for potential commercialization. The Company believes that achieving this manufacturing milestone represents an important step in reducing business and commercial execution risk as Bluejay advances toward regulatory submission and potential commercialization.
"Achieving this manufacturing milestone is an important accomplishment for Bluejay and another tangible step in our progression toward regulatory and commercial readiness," said Neil Dey, President and Chief Executive Officer of Bluejay Diagnostics. "Our manufacturing strategy is designed to extend beyond a single facility or geography. With the establishment of our manufacturing capability at SanyoSeiko and our strategic U.S. manufacturing relationship with ALURIS, we are working to build complementary manufacturing pathways that can provide greater flexibility, redundancy and supply-chain resilience."
Bluejay continues to advance its manufacturing scale-up activities alongside its regulatory program for the Symphony™ IL-6 Test, the Company's first product candidate.
The Symphony™ IL-6 Test has not been cleared or approved by the U.S. Food and Drug Administration ("FDA") and is not currently available for commercial clinical use in the United States. The Symphony™ rapid diagnostic platform is an investigational device and is limited by United States law to investigational use.
About the SYMON Clinical Study Program:
The SYMON Clinical Study Program includes SYMON-I (clinicaltrials.gov ID NCT06181604), SYMON-II (NCT06654895), and SYMON-III (NCT07425587). SYMON-I is a pilot study to determine IL-6 levels associated with various endpoints, including, but not limited to 28-day all-cause mortality and in-hospital mortality. The SYMON-II study is the pivotal study to validate the outcomes of the SYMON-I study, which the Company plans to use to support a 510(k) application to FDA. The SYMON-III study is a pilot study to determine IL-6 levels associated with patients presenting with increasing severity of infection in the emergency department and risk of developing sepsis.
About Bluejay Diagnostics:
Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony™ System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay does not yet have regulatory clearance for the Symphony™ System, and we will need to receive regulatory authorization from the U.S. Food and Drug Administration before Symphony™ can be marketed as a diagnostic product in the United States. Bluejay's first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from 'sample-to-result' to help medical professionals make earlier and better triage/treatment decisions. More information is available at www.bluejaydx.com.
Forward-Looking Statements:
This press release contains statements that the Company believes are "forward-looking statements" within the meaning of the Private Litigation Reform Act. Forward-looking statements may be identified by words such as "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "seeks," "should," "suggest," "will," and similar expressions. The Company has based these forward-looking statements on its current expectations and projections about future events, nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements the Company makes. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including market and other conditions and those discussed under item 1A. "Risk Factors" in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and in Part II, Item 1A, "Risk Factors" in its Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2026 and June 30, 2026. You should not place undue reliance on these forward-looking statements, as they are subject to risks and uncertainties, and actual results and performance in future periods may not occur or may be materially different from any future results or performance suggested by the forward-looking statements in this release. This press release speaks as of the date indicated above. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. The Company expressly disclaims any obligation to update or revise any forward-looking statements found herein to reflect any future changes in the Company's expectations of results or any future change in events, except as required by law.
Investor Contact:
Neil Dey
Bluejay Diagnostics, Inc.
ir@bluejaydx.com
Website: www.bluejaydx.com
SOURCE: Bluejay Diagnostics
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What manufacturing milestone did Bluejay Diagnostics achieve under its Toray agreement?
Bluejay completed establishment of a Symphony cartridge manufacturing site ahead of the October 23, 2026 contractual deadline. SanyoSeiko in Japan serves as the site under the amended Toray license agreement. Bluejay formally notified Toray that its obligation to substantially complete establishment of the site had been fulfilled.
How does Bluejay's SYMON-II study fit into its Symphony IL-6 Test regulatory plans?
Bluejay plans to use SYMON-II to support a 510(k) application to the FDA. SYMON-II is the pivotal study intended to validate outcomes from SYMON-I, a pilot study determining IL-6 levels associated with endpoints including 28-day all-cause mortality and in-hospital mortality.